OSAM
GALT icon

O'Shaughnessy Asset Management’s Galectin Therapeutics GALT Stock Holding History

O'Shaughnessy Asset Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,655
Closed -$18K – 2772
2021
Q2 		$18K Buy
+5,655
New +$20.1K ﹤0.01% 1865
2021
Q1 		– Sell
-72,515
Closed -$162K – 2399
2020
Q4 		$162K Buy
+72,515
New +$190K ﹤0.01% 906

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

O'Shaughnessy Asset Management's GALT Position: Q3 2021 in Review

O'Shaughnessy Asset Management sold out of Galectin Therapeutics (GALT) in Q3 2021, closing a stake of 5,655 shares — an estimated $18K sold.

O'Shaughnessy Asset Management first reported a position in GALT in Q4 2020 and held it in 2 quarters. The position peaked at $162K in Q4 2020. 70 funds tracked by Wall St. Rank hold GALT as of Q3 2021.

  • O'Shaughnessy Asset Management reported no remaining Galectin Therapeutics position as of Q3 2021 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 5,655 Galectin Therapeutics shares in Q3 2021, an estimated $18K.
  • O'Shaughnessy Asset Management first reported a position in Galectin Therapeutics in Q4 2020 and held it in 2 quarters.
  • O'Shaughnessy Asset Management's Galectin Therapeutics position peaked at $162K in Q4 2020.
  • 70 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.